BioStock: Arcede Pharma reports on the first quarter

After almost two months as a listed company, Arcede Pharma releases its first quarterly report. The first – and slightly shortened – quarter of the fiscal year has been marked by the spin-off from Respiratorius, but CEO Mia Lundblad also provides some operational updates. Among other things, she gives us some insight into the toxicological studies that are currently underway.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/09/arcede-pharma-reports-on-the-first-quarter/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se